Wells Fargo Upgrades Biogen to Overweight: Does the Alzheimer’s Story Finally Have a Second Act?

Biogen (NASDAQ:BIIB | BIIB Price Prediction) stock just earned a strong endorsement from Wells Fargo on Monday, as analyst Mohit Bansal upgraded the shares to Overweight from Equal Weight and raised his price target to $250 from $200. That’s a $50 target increase, and the reasoning marks a meaningful shift in how at least one corner of Wall Street is reading Biogen’s story.

Wells Fargo is making a longer-term call, pointing to new medium-term growth drivers emerging from Biogen’s late-stage pipeline outside of neurology, rather than near-term momentum in existing launches. For investors watching the company lean heavily on its Alzheimer’s franchise, that’s a notable pivot in the narrative.

The Analyst’s Case

Wells Fargo believes Biogen’s new revenue streams from its immunology and kidney pipelines reduce its reliance on Alzheimer’s, which has long been both the company’s most exciting asset and its most unpredictable one. Wells Fargo sees these late-stage programs as credible medium-term growth drivers that the market hasn’t fully priced in yet.

Other firms are also warming to Biogen. Piper Sandler also upgraded Biogen stock to Overweight on April 14, raising its price target from $177 to $214, citing improved growth prospects and a revenue forecast of over $10.5 billion by 2027. Two Overweight upgrades in less than a week signal growing conviction that Biogen’s transformation is real.

Company Snapshot

Biogen is a Cambridge, Massachusetts-based biotechnology company specializing in neurological and rare disease treatments. Roughly 45% of its product revenue now comes from outside the MS franchise, a meaningful shift from just a few years ago. Full-year 2025 revenue came in at $9.891 billion, with non-GAAP EPS of $15.28.

LEQEMBI global in-market sales reached approximately $134 million in Q4 2025, up 54% year over year, while ZURZUVAE grew 158% year over year in the same period. The MS franchise continues to face headwinds, with MS product revenue declining 14% year over year in Q4 2025, which is precisely why pipeline diversification matters so much.

Why the Move Matters Now

Biogen stock is trading at a forward P/E ratio of 12x, well below its trailing multiple, suggesting the market is pricing in continued revenue pressure. The consensus analyst price target sits at $207.69, with 15 analysts rating the stock a Buy and 20 at Hold. Wells Fargo’s $250 target stands well above consensus, reflecting a more aggressive view of what the pipeline could deliver.

Biogen also announced today it acquired exclusive China rights to felzartamab from TJ Biopharma for $100 million upfront and up to $750 million in potential milestones, adding another data point to the immunology diversification thesis Wells Fargo is backing.

What It Means for Your Portfolio

The Wells Fargo upgrade suggests Biogen’s case as a diversified biotech — extending beyond its Alzheimer’s franchise — is starting to take shape. The immunology and kidney pipeline could offer a genuinely new growth runway, but pipeline execution always carries risk, and total revenue is still expected to decline mid-single digits in 2026.

Watch for whether the late-stage pipeline readouts deliver on their promise. For long-term BIIB stock investors comfortable with biotech volatility, the revised outlook from Wells Fargo warrants a closer look, even as near-term revenue headwinds remain a real consideration.